Developing biologic drugs often presents the challenge of mitigating immune responses against these therapies, a hurdle that innovative research within the fields of immunology and inflammation is striving to overcome. Recent funding rounds highlight the ongoing efforts of various startups to advance novel therapeutic candidates towards clinical applications. Here’s a recap of some key financing announcements segmented by therapeutic area:
- Immunology & Inflammation
- Jade Biosciences secured $80 million in financing to develop targeted therapies for autoimmune diseases. The startup emerged from Paragon Therapeutics and is backed by Fairmount Funds and Venrock Healthcare Capital Partners.
- SciRhom raised €63 million (approximately $70 million) to further its research in autoimmune disease therapies targeting the TACE/ADAM17 pathway.
- Santa Ana Bio announced $168 million in total financing to develop precision medicines for autoimmune and inflammatory diseases. The financing was led by Versant Ventures and GV.
- Oncology
- Outpace Bio garnered $144 million to advance AI-powered cell therapies targeting solid tumors into clinical development. The Series B financing was led by RA Capital Management.
- Scorpion Therapeutics and CatalYm each raised $150 million, with funds directed towards respective cancer drug pipelines. Scorpion’s Series C round focused on STX-478, a drug for solid tumors with PI3K alpha mutations, while CatalYm plans to advance visugromab, an antibody targeting the GDF-15 protein, into broad Phase 2b trials.
- Cardiometabolic Disease
- Confo Therapeutics, focused on GPCR-targeting small molecules and antibodies, closed a €60 million financing round to advance its pipeline. The Series B funding was led by Ackermans & van Haaren.
- Cardurion Pharmaceuticals raised $260 million to continue the clinical development of its lead heart drug candidates: CRD-750 and CRD-4730. The Series B round was led by Ascenta Capital.
- Neuroscience
- Brenig Therapeutics secured $65 million to propel its lead Parkinson’s disease drug, BT-267, into early clinical development. The financing was led by New Enterprise Associates.
- Asceneuron closed $100 million to support Phase 2 testing of ASN51, a tau aggregation inhibitor for Alzheimer’s disease.
- Eye Disorders
- Beacon Therapeutics raised $170 million to advance its gene therapies for inherited retinal diseases, focusing on AGTC-501 for X-linked retinitis pigmentosa, now in Phase 2/3 testing.
The capital influx across these therapeutic areas underscores the sustained interest and investment in advancing biotechnological innovations. For further details on these financings, visit MedCity News.